**Cookie notice**

Close

This website uses cookies to help us give you the best experience when you visit our website. By continuing to use this website, you consent to our use of these cookies.  
Find out more about how we use cookies and how to manage them by reading our cookie notice.

[About our use of cookies](http://openinnovation.astrazeneca.com/about-us/what-are-cookies-and-how-does-openinnovation-astrazeneca-com-use-them/" \t "_blank)Continue

[Open Innovvations - AstraZenecamobilelogo - Open Innovations](http://openinnovation.astrazeneca.com/)

**Table of Compounds Draft（化合物名か一番右にあるファイルをクリックすると詳細情報を見ることが出来ます）。**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| [**Compound**](javascript:;) | [**Mechanism of Action**](javascript:;) | [**Target Class**](javascript:;) | [**Originating Disease**](javascript:;) | [**Original Indication**](javascript:;) | [**Route**](javascript:;) | [**CNS Penetrant**](javascript:;) |  |
| [AZD4017](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd4017/) | 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/3290" \t "_blank) | Enzyme | CVMD | Diabetes | Oral | Low |  |
| [AZD8329](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8329/) | 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/3290" \t "_blank) | Enzyme | CVMD | Diabetes | Oral | Low |  |
| [AZD3463](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd3463/) | Anaplastic lymphoma tyrosine kinase (ALK) and insulin growth factor1 receptor (IGF1R) tyrosine kinase inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/238%20" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/3480%20" \t "_blank" \o "More) | Kinase | Oncology | Non-Small Cell Lung Cancer (NSCLC) | Oral | Unknown |  |
| [AZD4320](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd4320/) | B-cell lymphoma 2 (Bcl-2) and Bcl-2-like protein 1 (Bcl2L1 or BclxL) binding inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/596%20" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/598%20" \t "_blank" \o "More) | Apoptotic | Oncology | Oncology | Oral | Unknown |  |
| [AZ12419304](http://openinnovation.astrazeneca.com/what-we-offer/compound/az12419304/) | B-Raf serine/threonine-protein kinase (BRAF) and V600E mutation inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/673%20" \t "_blank" \o "More) | Kinase | Oncology | Oncology | Oral | Unknown |  |
| [AZ12823138](http://openinnovation.astrazeneca.com/what-we-offer/compound/az12823138/) | B-Raf serine/threonine-protein kinase (BRAF) V600E mutant inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/673%20" \t "_blank" \o "More) | Kinase | Oncology | Oncology | Oral | Unknown |  |
| [AZD7762](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd7762/) | Checkpoint kinase 1 and 2 (Chk1/2) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/1111" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/11200%20" \t "_blank" \o "More) | Kinase | Oncology | Solid and Haematological Tumours | IV | Low |  |
| [AZD1981](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1981/) | Chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) antagonist [prostaglandin D2 (DP2) receptor antagonist] [More](http://www.ncbi.nlm.nih.gov/gene/11251" \t "_blank) | GPCR | Inflammation | Asthma, COPD | Oral | Low |  |
| [AZD6495](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd6495/) | Colony stimulating factor-1 receptor (CSF-1R) tyrosine kinase inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/1436%20" \t "_blank" \o "More) | Kinase | Oncology | Oncology | Oral | Unknown |  |
| [Zibotentan (ZD4054)](http://openinnovation.astrazeneca.com/what-we-offer/compound/zd4054-zibotentan/) | Endothelin receptor A (ETA) antagonist [More](http://www.ncbi.nlm.nih.gov/gene/1909" \t "_blank) | GPCR | Oncology | Castration-Resistant Prostate Cancer (CRPC) | Oral | Low |  |
| [AZ12609721](http://openinnovation.astrazeneca.com/what-we-offer/compound/az12609721/) | Ephrin receptor B4 (EphB4) tyrosine kinase inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/2050%20" \t "_blank" \o "More) | Kinase | Oncology | Oncology | Oral | Unknown |  |
| [AZD8931](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8931/) | Epidermal growth factor receptor (EGFR) family (pan-erbB) tyrosine kinase inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/1956" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/2064" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/2065%20" \t "_blank" \o "More) | Kinase | Oncology | Solid Tumours | Oral | Low |  |
| [AZD7325](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd7325/) | Gamma-aminobutyric acid receptor A alpha 2 & 3 (GABAAα2,3) positive modulator [More](http://www.ncbi.nlm.nih.gov/gene/2555" \t "_blank); [More](http://www.ncbi.nlm.nih.gov/gene/2556" \t "_blank) | Ligand-gated ion channel | CNS | General Anxiety Disorder | Oral | Yes |  |
| [Lesogaberan (AZD3355)](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd3355-lesogaberan/) | Gamma-aminobutyric acid receptor B (GABAB) agonist [More](http://www.ncbi.nlm.nih.gov/gene/2250" \t "_blank); [More](http://www.ncbi.nlm.nih.gov/gene/2250" \t "_blank) | Ligand-gated ion channel | GI | GERD | Oral | Low |  |
| [AZD1656](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1656/) | Glucokinase (GK; hexokinase 4) activator [More](http://www.ncbi.nlm.nih.gov/gene/2645" \t "_blank) | Enzyme | CVMD | Diabetes | Oral | Low |  |
| [AZD1480](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1480/) | Janus kinase 1 and 2 (JAK1/2) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/3716" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/3717%20" \t "_blank" \o "More) | Kinase | Oncology | Solid Tumours; Myeloproliferative Diseases | Oral | Yes |  |

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| [AZD4877](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd4877/) | Kinesin spindle protein (KSP; also called Eg5) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/3832%20" \t "_blank" \o "More) | Enzyme | Oncology | Haematopoietic and Solid Malignancies | IV | Low |  |
| [AZ12260493](http://openinnovation.astrazeneca.com/what-we-offer/compound/az12260493/) | Liver X receptor (LXRa/b; also NR1H3/2) agonist [More](http://www.ncbi.nlm.nih.gov/gene/10062" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/7376" \t "_blank" \o "More) | Nuclear Receptor | CVMD | Dyslipidaemia | Oral | Unknown |  |
| [AZD8055](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8055/) | Mammalian target of rapamycin (mTOR) kinase (TORC1/2) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/2475" \t "_blank" \o "More) | Kinase | Oncology | Relapse / Refractory Cancer | Oral | Low |  |
| [AZD1236](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1236/) | Matrix metalloproteinase 9 & 12 (MMP9,12) inhibitor [MMP9](http://www.ncbi.nlm.nih.gov/gene/4318" \t "_blank) [MMP12i](http://www.ncbi.nlm.nih.gov/gene/4321" \t "_blank) | Enzyme | Inflammation | COPD | Oral | Low |  |
| [AZD3857](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd3857/) | Melanin concentrating hormone receptor 1 (MCH1) antagonist and acetylcholinesterase (AChE) inhibitor [MCH1](http://www.ncbi.nlm.nih.gov/gene/2847" \t "_blank" \o "MCH1) [AChE](http://www.ncbi.nlm.nih.gov/gene/43" \t "_blank" \o "AChE) | GPCR | CVMD | Obesity | Oral | Yes |  |
| [AZ13483342](http://openinnovation.astrazeneca.com/what-we-offer/compound/az13483342/) | Melanin concentrating hormone receptor 1 (MCH1) antagonist [MCH1](http://www.ncbi.nlm.nih.gov/gene/2847%20" \t "_blank" \o "MCH1) | GPCR | CVMD | Obesity | Oral | Yes |  |
| [AZD8529](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8529/) | Metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator [More](http://www.ncbi.nlm.nih.gov/gene/2912" \t "_blank) | GPCR | CNS | Schizophrenia | Oral | Yes |  |
| [AZD5904](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd5904/) | Myeloperoxidase (MPO) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/4353" \t "_blank) | Enzyme | Inflammation | COPD, MS | Oral | Low |  |
| [AZD1332](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd1332/) | Neurotrophic tyrosine kinase receptor (NTRK; or Tropomycin-related kinase,Trk) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/4914" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/4915" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/4916%20" \t "_blank" \o "More) | Kinase | Oncology | Oncology | Oral | Unknown |  |
| [AZD9668](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd9668/) | Neutrophil elastase (NE) inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/1991" \t "_blank) | Enzyme | Inflammation | COPD, Cystic Fibrosis | Oral | Low |  |
| [AZD0328](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd0328-2/) | Nicotinic acetylcholine receptor alpha 7 (α7 nAChR) agonist [More](http://www.ncbi.nlm.nih.gov/gene/1139" \t "_blank) | Ligand-gated ion channel | CNS | Cognitive impairment | Oral | Yes |  |
| [AZ11657312](http://openinnovation.astrazeneca.com/what-we-offer/compound/az11657312/) | Purinergic receptor 2X, ligand-gated ion channel 7 (P2X7) antagonist [More](http://www.ncbi.nlm.nih.gov/gene/5027" \t "_blank) | Ligand-gated ion channel | Inflammation | COPD, Crohn's, OA, RA | Oral | Low |  |
| [AZD5582](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd5582/) | Second mitochondria-derived activator of caspase (Smac) mimetic [inhibitor of apoptosis protein (IAP) antagonist] [More](http://www.ncbi.nlm.nih.gov/gene/56616%20" \t "_blank" \o "More) | Apoptotic | Oncology | Solid Tumours | IV | Unknown |  |
| [AZD8542](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd8542/) | Smoothened (SMO), frizzled family receptor antagonist [More](http://www.ncbi.nlm.nih.gov/gene/6608" \t "_blank" \o "More) | GPCR | Oncology | Oncology | Oral | Unknown |  |
| [Saracatinib (AZD0530)](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd0530-saracatinib-2/) | Src tyrosine kinase family inhibitor [More](http://www.ncbi.nlm.nih.gov/gene/6714" \t "_blank) | Kinase | Oncology | Oncology | Oral | Low |  |
| [AZD2927](http://openinnovation.astrazeneca.com/what-we-offer/compound/azd2927/) | Acetylcholine-regulated inwardly rectifying potassium current (IKACh) blocker [More](http://www.ncbi.nlm.nih.gov/gene/3760" \t "_blank" \o "More) [More](http://www.ncbi.nlm.nih.gov/gene/3762" \t "_blank" \o "More) | Ligand-gated ion channel | CVMD | Atrial fibrillation | IV | Low |  |